A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

RC21_0169

This is a phase II, multicenter, open-label study to evaluate the rate of patients achieving very good partial response (VGPR) or better to the oral combination Iberdomide Ixazomib Dexamethasone in elderly patients with multiple myeloma at first relapse . The patient population will consist of adult men and women more than 70 years, who meet eligibility criteria. Following the screening period, patients will be enrolled and treated then, they will receive therapy with Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression.

2021-12-14

2025-01-01

2027-01-01

Active (not recruiting)

Early phase I

80

Inclusion Criteria: 1. Age \> 70 years 2. Eastern Collaborative Oncology Group (ECOG) performance score of ≤2 3. Life expectancy \> 6 months 4. Voluntary written informed consent must be given before performance of any study-related procedure not part of normal medical care, with the understanding that the subject may withdraw consent at any time without prejudice to future medical care. 5. Symptomatic multiple myeloma (MM) at first relapse, as defined below: * Symptomatic multiple myeloma according to international criteria.(Rajkumar et al, 2014) * Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy. 6. Subject must have received one prior line of therapy for at least 3 cycles. 7. Subject has measurable disease at Screening, defined at least one of the following: * Serum M-protein ≥ 0.5 gram (g)/deciliter (dL), OR * Urine M-protein ≥ 200 mg in 24 hours, OR * Serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL provided serum FLC ratio is abnormal. 8. Subjects must meet the following laboratory parameters, per laboratory reference range (performed at most 15 days before cycle 1 day 1): * Absolute neutrophil count (ANC) ≥ 1000/microliter (μL). Subjects may use growth factor support to achieve ANC eligibility criteria. * Platelet count ≥ 75,000 /mm3 for subjects in whom \< 50% of bone marrow nucleated cells are plasma cells; or a platelet count ≥ 50,000/mm3 for subjects in whom \> 50% of bone marrow nucleated cells are plasma cells. It is not permissible to transfuse subjects to achieve minimum platelet counts within 3 days before study. --AST and ALT ≤ 3 × upper limit of normal (ULN). * Total bilirubin ≤ 1.5 × ULN. Subjects with documented Gilbert's syndrome may have bilirubin \> 1.5 × ULN with the approval of the Primary Therapeutic Area Medical Director * Creatinine clearance (CrCl) ≥ 30 milliliter (mL)/minute (min) (using Cockroft and Gault Formula) 9. Patient should comply with Celgene's pregnancy prevention plan for Iberdomide (please see appendix 8 Iberdomide Pregnancy Prevention Plan for subjects in clinical trials) 10. Female patients who: * are postmenopausal for at least 24 months before the screnning visit, OR * are surgically sterile (have undergone a hysterectomy or bilateral oophorectomy) 11. Men even if surgically sterilized must agree to not father a child and agree to practice complete abstinence or to use a condom during therapy and dose interruptions and for 90 days after the last dose of study drug, even if they have had a successful vasectomy, if their partner is of childbearing potential or pregnant. Non-inclusion Criteria: 1. Subject is refractory to bortezomib, defined as progression on or within 60 days of the last dose of bortezomib. 2. Subject has had prior treatment with ixazomib, carfilzomib, pomalidomide or iberdomide 3. Subject has any of the following conditions: * Non-secretory or oligo-secretory MM * Light chain Amyloidosis (AL Amyloidosis) * POEMS syndrome Waldenström macroglobulinemia 4. Known Human Immunodeficiency Viral (HIV) infection 5. Active hepatitis B or C infection based on blood screen tests 6. Significant cardiovascular or pericardial disease, including uncontrolled angina, hypertension, arrhythmia, recent myocardial infarction within 6 months, congestive, heart failure New York Heart Association (NYHA) Class ≥ 3 7. Major surgery within 4 weeks prior screening 8. Acute infections requiring parenteral therapy (antibiotic, antifungal or antiviral) within 14 days 9. ≥ Grade 3 Peripheral neuropathy or grade 2 with pain 10. Uncontrolled diabetes or uncontrolled hypertension within 14 days 11. Any other medical condition that, in the opinion of the Investigator, would adversely affect the subject's participation in the study 12. Subject has a history of other active malignancies, including myelodysplastic syndrome (MDS), within the past 3 years prior to study entry, with the following exceptions: * Adequately treated in situ carcinoma of the cervix uteri or the breast, * Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin, * Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen (PSA) levels off treatment, * Previous malignancy with no evidence of disease confined and surgically resected (or treated with other modalities) with curative intent and unlikely to impact survival during the duration of the study. 13. Known intolerance to steroid therapy 14. Serious medical or psychiatric illness likely to interfere with participation in study 15. Incidence of gastrointestinal disease that may significantly alter the absorption of oral drugs 16. Subjects unable or unwilling to undergo antithrombotic prophylactic treatment 17. Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 80, 'type': 'ESTIMATED'}}

2023-05-30